Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,470 across all filing types
Latest filing 2024-01-26 Transaction in Own Shar…
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It details multiple repurchases of shares over various dates, including quantities and prices, and confirms compliance with listing rules of the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase transactions and changes in issued shares, with no financial statements or earnings data. This matches the description of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is over 12,000 characters and contains detailed transactional data, not just an announcement or certification, so it is not a Regulatory Filing or Report Publication Announcement. Therefore, the correct classification is 'POS' (Transaction in Own Shares).
2024-01-26 English
VOLUNTARY ANNOUNCEMENT - ASCLETIS ANNOUNCES DOSING OF THE FIRST PATIENT IN PHASE III CLINICAL TRIAL OF ASC40 (DENIFANSTAT) FOR TREATMENT OF ACNE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ascletis Pharma Inc. regarding the dosing of the first patient in a Phase III clinical trial for a drug candidate (ASC40) for acne treatment. It provides details about the clinical trial design, endpoints, and prior Phase II results. There is no financial data, no regulatory filing references, no voting results, no management changes, no earnings or annual report content. The document is an update on business development and clinical progress, typical of a voluntary business update or regulatory announcement. The document length is 3390 characters, which is relatively short and reads as an announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Report. It is not a regulatory compliance filing or certification. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements and voluntary business updates that do not fit other categories.
2024-01-24 English
DISCLOSEABLE TRANSACTION GRANTING OF LOAN
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a loan agreement entered into by a subsidiary of the company. It details the terms of the loan, the parties involved, the amount, interest rate, repayment terms, and the implications under the Listing Rules. The document is a disclosure of a financial transaction (granting of loan) and is not a full financial report, earnings release, or management discussion. It is not a report publication announcement since it contains substantive details about the transaction itself. The document fits the category of Capital/Financing Update (CAP) as it provides an update on the company's financing activities related to granting a loan, which is a capital transaction. The length and detail support this classification with high confidence.
2024-01-23 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed data on repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase transactions and capital changes rather than financial results, management changes, or other report types. This matches the definition of a 'Transaction in Own Shares' filing, which reports company buybacks or sales of its own shares. The document length is substantial and contains detailed transactional data, confirming it is the report itself, not just an announcement. Therefore, the correct classification is POS (Transaction in Own Shares).
2024-01-22 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations of compliance with listing rules on the Stock Exchange of Hong Kong. The content focuses on reporting share repurchase activities and changes in issued shares, which aligns with announcements regarding share buybacks or capital changes. There is no indication of a full financial report, earnings release, or management discussion. The document is a regulatory disclosure about share repurchases and capital changes, fitting the category of 'Transaction in Own Shares' (POS). The document length is substantial and contains detailed transactional data, confirming it is not a mere announcement or certification but a substantive report of share repurchase transactions.
2024-01-19 English
Next Day Disclosure Return
Transaction in Own Shares Classification · 100% confidence The document is titled 'Next Day Disclosure Return' and relates to changes in issued share capital and share buybacks by Ascletis Pharma Inc. It includes detailed tables of repurchases of shares, dates, quantities, prices, and confirmations that these repurchases comply with listing rules of the Stock Exchange of Hong Kong. The document is a regulatory disclosure about share repurchases, not a full financial report or earnings release. It is not an announcement of a report publication but a substantive regulatory filing about share transactions. This fits the category of Transaction in Own Shares (POS), which covers reports of the company buying back or selling its own shares.
2024-01-18 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.